SureTrader
Home > Boards > US OTC > Biotechs >

NanoLogix, Inc. (NNLX)

NNLX RSS Feed
Add NNLX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/21/2018 1:40:33 PM - Followers: 133 - Board type: Free - Posts Today: 0


ABOUT NANOLOGIX 

The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.

Uses for NanoLogix's very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.

NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.


Mission

NanoLogix is a biotechnology company focused on sale of Petri plates packaged in an exclusive licensed FlatPack and the N-Assay rapid detection technology for bacteria, mold, and spores.

NanoLogix technology is used to test for bacteria and other microorganisms and in some cases, dependent upon the technology used, provide for early detection of bacteria and other microorganisms present in infectious and noninfectious human diseases, the environment, industrial and manufacturing settings, veterinary medicine, and research and testing laboratories.


History

NanoLogix began 26 years ago under the name Infectech. From its founding through 2007 the Company had been issued patents that were in some cases practically, and in other cases theoretically, applicable in the areas of applied microbiology, soil microbiology, medical diagnostics, microbial physiology, pharmacology, pharmaco-kinetics, and determination of antibiotic sensitivity.

In 2007, with a management change, the focus of the company changed from Research and Development to exploring how to capitalize on the company's existing intellectual property. It became obvious that the patents of the past possessed little monetary value for the future and that realization resulted in a further change in direction seeking to focus on practicality in research and a focus on a long term future return for the company and its shareholders. The period from 2007 through 2011 resulted in the abandonment of any focus on the production of hydrogen through bacteria degradation of organic waste utilizing what was referred to as a "bioreactor". The reason for the abandonment of the technology was the discovery of a lack of evidence for any economic potential for the technology. A similar discovery led to the practical abandonment of the NanoLogix BNC (BioNanoChannel) technology. While potentially a novel approach to diagnostics, major-lab third-party tests and a subsequent economic analysis demonstrated that under no conditions could the cost of both the antibody coating and specialized glass microchannel disc contained in the apparatus be reduced to a level to enable effective marketing.   Over the following year, NanoLogix went through a transition to production of FlatPack™ Petri plates and BNP™ diagnostic test kits. Sales of both began in Q3 2012.

NanoLogix's rapid diagnostic technology is the N-Assay modified ELISA diagnostic.


NanoLogix Technology

NanoLogix N-Assay technology provides live-cell rapid detection and identification dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, in contrast to other fast methods such as Polymerase Chain Reaction (PCR), NanoLogix technology does not require large investments in equipment or personnel training.

Rapid diagnostics allow researchers in the lab to test for potentially pathogenic agents faster and develop effective countermeasures more rapidly and economically. This quality presents exciting opportunities in the pharmaceutical design process, and furnishes the following as benefits:

Can begin more effective drug treatment when an infectious disease is identified at an early stage. The spread of infectious disease may be reduced by earlier intervention.

In combat theaters and homeland security settings, the presence of specific pathogens can be detected closer to the epicenter of release. Site decontamination teams can identify surface samples closer to real time, potentially aiding the field process.

Industrial production
of food, beverage, drugs, or beauty productscan be paralyzed by microbial contamination.  The ripple effect may include expensive recalls, bad publicity, and government mandated "microbiology holds" that delay the replacement of product.  Rapid diagnostics can help minimize the impact by limiting the spread of spoiled product.


Market

The volume of Petri dishes used for traditional tests is millions per day worldwide.

According to Industrial Microbiology Market Review, worldwide industrial microbiology testing is undergoing tremendous growth. The same growth pattern is anticipated in the medical microbiological diagnostics market.

NanoLogix's potential customers are numerous and varied. They include microbiological laboratories in the industrial, medical, environmental, governmental (federal, state and local) sectors, research and development facilities, and educational institutions.


R&D

NanoLogix's research and development continues on other diagnostic technology with variants in the N-Assay currently being developed for one of the world's largest medical device companies.


Research Articles

Development of a Novel Test for Simultaneous Bacterial Identification and Antibiotic Susceptibility

Jonathan Faro,1 Malika Mitchell,2 Yuh-Jue Chen,2 Sarah Kamal,2 Gerald Riddle,1 and Sebastian Faro1

1 The Woman’s Hospital of Texas, 7400 Fannin Suite 930, Houston, TX 77054, USA
2 The University of Texas Health Science Center at Houston, Medical College, Houston, TX 77054, USA


Received 13 May 2016; Accepted 10 August 2016

Abstact

Background. Elucidation of a pathogen’s antimicrobial susceptibility requires subculture after the organism is first isolated. This takes several days, requiring patients to be treated with broad-spectrum antibiotics. This approach contributes to the development of bacterial resistance. Methods. Microtiter wells were coated with a polyclonal antibody targeting the pathogen of interest. Bacterial suspensions were added in the presence/absence of selected antibiotics. After washing, captured bacteria were detected. Findings. Group B streptococcus (GBS), Enterococcus faecalis, and Neisseria gonorrhoeae were each detected at 105 bacteria/mL following a 20-minute incubation period. Susceptibility to select antibiotics was discernable following a 6-hour incubation period (GBS and Enterococcus). Sensitivity was increased to 10−2 bacteria/mL for GBS, 10−1 bacteria/mL for E. faecalis, and 101 bacteria/mL for N. gonorrhoeae following 18–24-hour culture. Conclusion. This novel assay allows for the highly sensitive and specific identification of a pathogen and simultaneous determination of its antimicrobial susceptibility in a reduced time.


Shelf-Life Assessment of Agar Plates Vacuum-Sealed in Nylon/Polyethylene Packaging Flushed with Nitrogen
Young W. Choi and James V. Rogers
Battelle’s Biomedical Research Center, Columbus, USA

Received: October 23, 2015 | Published: December 29, 2015

Abstract

In resource-limited nations, enhancing the shelf-life and stability of critical reagents and consumables is desired. This study evaluated the shelf-life of bacteriological plates in vacuum-sealed nylon/polyethylene packaging flushed with nitrogen (FlatPacks®). Tryptic soy agar (TSA) FlatPacks held at room temperature for 24 months did not change in appearance or texture and supported bacterial growth similar to Day 0 concentrations. In contrast, TSA plates from a different supplier (Vendor A) desiccated after 4 months of storage at room temperature. TSA, blood agar (BA), and chocolate agar (CA) FlatPacks subjected to desert-like storage and transport temperatures (60 °C) for 30 days supported bacterial growth similar to FlatPacks held at room temperature or refrigerated; TSA, BA, and CA plates (Vendor A) desiccated within 7 days. The data suggest FlatPacks extend the shelf-life of TSA stored at room temperature when compared to traditional packaging. Additionally, TSA, BA, and CA FlatPacks support bacterial growth for at least 30 days when stored at 60 °C. Based on the results of this study, the FlatPacks may help laboratories in resource-limited nations overcome infrastructure, refrigeration, and supply-chain deficiencies. 



Preliminary Evaluation of Mycobacterium tuberculosis Detection in Culture and Artificial Sputum Using a BioNanoPore Membrane and Realtime PCR
James V. Rogers and Young W. Choi
Battelle, Biomedical Research Center, 505 King Ave, JM-7, Columbus, OH 43201, USA 

Received October 26, 2012; Accepted November 20, 2012

Abstract

The rapid detection and diagnosis of Mycobacterium tuberculosis is critical to evaluate disease severity, efficacy of treatments and therapeutics, and public health monitoring. This study evaluated a BioNanoPore technology (BNP™ Middlebrook agar) to detect and quantitate M. tuberculosis in less time than traditional plate counting methods. BNP™ Middlebrook enabled visual detection of M. tuberculosis from actively-growing cultures and inoculated artificial sputum within 5 days; however, colonies were not visible on Middlebrook 7H10 agar. For cultures incubated in the presence or absence of artificial sputum for 19 days on BNP™ Middlebrook, M. tuberculosis ranged from 5.81-5.86 log10CFU/mL from liquid culture and 6.39-6.50 log10CFU/mL in artificial sputum; counts for M. tuberculosis in liquid culture ranged from 5.70-5.85 log10CFU/mL on Middlebrook 7H10. All colonies from 19 day-old cultures evaluated from the BNP™ Middlebrook and Middlebrook 7H10 media were positive for the Mycobacterium insertion sequence (IS) 6110 by real-time PCR. This study demonstrates that BNP™ Middlebrook can detect M. tuberculosis faster than standard plating techniques in the presence or absence of a simulated biological matrix (artificial sputum). Moreover, the BNP™ Middlebrook color development step does not interfere with real-time PCR detection of IS 6110. This study provides a preliminary assessment of the potential use of BNP™ Middlebrook for a more rapid screening and detection of viable M. tuberculosis with respect to clinical specimen evaluation, therapeutic treatment/vaccine efficacy, or epidemiological surveillance.



Decreased time for detection and quantification of virulent Bacillus anthracis and Yersinia pestis using a BioNanoPore (BNP™) membrane technology
James V. Rogers
Battelle Memorial Institute, Biomedical Research Center, 505 King Avenue, JM-7, Columbus, OH 43201, USA


Received 1 December 2008, Revised 2 February 2009 and Accepted 7 February 2009


Abstract

Many aspects of biodefense research require quantitative growth assessments of the test agent. This study evaluated the BioNanoPore (BNP™) technology to quantitate Bacillus anthracis and Yersinia pestis faster than traditional plate counting methods. The BNP™ technology enabled quantification of B. anthracis and Y. pestis in phosphate-buffered saline and naïve rabbit blood at 6 and 24 h, respectively. After 6 h of growth, counts for B. anthracis ranged from 6·19–6·45 log10 CFU ml−1 on BNP™, while counts after 24 h on tryptic soy agar (TSA) ranged from 6·51–6·58 log10 CFU ml−1. For Y. pestis, counts on BNP™ at 24 h ranged from 6·31–6·41 log10 CFU ml−1 on BNP™ and ranged from 6·44–6·89 log10 CFU ml−1 on TSA at 48 h. This study demonstrates that the BNP™ technology provides a more rapid detection of B. anthracis and Y. pestis, which could aid in the evaluation of potential medical countermeasures and treatments as well as other biological defense applications such as surface sampling or decontamination efficacy.



Patents

A partial list of Infectech's (now NanoLogix) patents:

http://nanologix.com/downloads/resources_patents.pdf


United States patents that are assigned to NanoLogix:


Production of hydrogen gas and isolation of hydrogen producing microorganisms using replenishing coated substrates - Patent
7,473,552

Method and device for rapid detection of microorganisms by changing the shape of micro-colonies - Patent 7,524,623

Micromethod and device for rapid detection, enumeration and identification of entities - Patent 7,781,159

Method and device for rapid detection of microorganisms by changing the shape of micro-colonies in micro-channels - Patent 8,067,154

Micromethod and device for the rapid detection, enumeration and identification of microorganisms - Patent 8,361,783

Apparatus for making a solid nutrient medium and associated method - Patent 8,420,384

Device for rapid detection and identification of single microorganisms without preliminary growth - Patent 8,663,909


United States patents that are licensed to NanoLogix:

Flat Packaging of Petri Dishes for Prolonged Preservation and Method of Producing the Same - Patent 8,413,900


Rapid enzyme-linked immunosorbent assay for detection and identification of pathogens and determination of antimicrobial susceptibility - Patent
9,034,583

Methods and devices for rapid detection and identification of live microorganisms by aptamers and/or antibodies immobilized on permeable membranes - Patent 9,068,216


Share Structure

Estimated Market Cap: $10,936,066 as of Aug.8, 2017.

Outstanding Shares: As of Aug.8 2017, the company has 145,814,222 shares outstanding. Shares outstanding on December 31, 2014 were 139,531,530 shares.


Restricted shares: 34,484,859 shares as of Aug.8, 2017.

Authorized Shares: 200,000,000 as of Aug.8, 2017.

Number of Shareholders of Record: 2,000+/- shareholders as of end of 2015.


Press Releases and Company Updates


http://nanologix.com/news/press_releases.html

http://nanologix.com/news/updates.html



Price Quote

http://www.investorshub.com/boards/quotes.asp?ticker=NNLX


NNLX Charts

(1 month daily, 3 month daily, 1 year weekly)




_________________________________________________________________________________________________________________________________________

Contacts

NanoLogix Inc.
843 North Main Street
Hubbard, OH 44425 USA
330-534-0800 (main line)
330-534-0826 (fax)

info@nanologix.com

Pacific Stock Transfer
6725 Via Austi Parkway
Suite 300
Las Vegas, NV 89119
800-785-7782
info@pacificstocktransfer.com
 
SureTrader
NNLX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#9922   I never said I brought in May 2005. drugmanrx 04/21/18 01:40:33 PM
#9921   Emerald Isle 04/21/18 12:41:12 PM
#9920   If you bought in May 2005 you did Emerald Isle 04/21/18 12:41:11 PM
#9919   No, I brought for the petri dish. drugmanrx 04/21/18 12:13:02 PM
#9918   Drugman, So you bought in at the height of Emerald Isle 04/21/18 12:11:35 PM
#9917   Drugman, So you bought in at the height of Emerald Isle 04/21/18 12:11:35 PM
#9916   EI I am glad you are amused. drugmanrx 04/21/18 12:04:56 PM
#9915   Drugman, I have to say I’m laughing. You say Emerald Isle 04/21/18 10:29:32 AM
#9914   "They go to subscribers and also are available drugmanrx 04/21/18 08:18:56 AM
#9913   You know what, it's good thing for the exploremore 04/20/18 07:10:39 PM
#9912   Read these updates. They really need help with exploremore 04/20/18 07:01:57 PM
#9911   Drugman, "I don't subscribed to their update newsletter because Emerald Isle 04/20/18 01:24:22 PM
#9910   I don't subscribed to their update newsletter because drugmanrx 04/20/18 11:13:59 AM
#9909   Drugman, No doubt whatsoever. The expansion plans press release Emerald Isle 04/20/18 10:47:29 AM
#9908   Drugman, Emerald Isle 04/20/18 10:38:10 AM
#9907   The good news is that fees have been yman 04/20/18 10:18:34 AM
#9906   Emerald. I guess I wasn't the only share holder drugmanrx 04/20/18 09:33:00 AM
#9905   Care to supply an official company release link. drugmanrx 04/20/18 09:19:34 AM
#9904   "I wonder what the collateral was?" exploremore 04/20/18 05:52:21 AM
#9902   Just saw this update: Emerald Isle 04/19/18 10:58:10 PM
#9901   drugmanrx: Agree with a thru d. yman 04/18/18 03:34:03 PM
#9900   Emerald your energies are misplaced. drugmanrx 04/18/18 11:33:52 AM
#9899   Thanks,,,,, I guess. exploremore 04/17/18 10:05:26 PM
#9898   Exploremore, 1) Which technology was paid for? Emerald Isle 04/17/18 12:54:18 PM
#9897   Which technology was paid for? For what purpose? exploremore 04/17/18 06:25:22 AM
#9896   "I know companies that have paid for and drugmanrx 04/16/18 07:48:29 PM
#9895   EI, do you think that once the Time rckuehn 04/16/18 05:36:21 PM
#9894   EI: My point was a simple one. yman 04/16/18 04:42:18 PM
#9893   Looks like that'd be B Scientific or Medtronic jshdn 04/16/18 02:45:16 PM
#9892   One is a multi billion dollar player in Emerald Isle 04/16/18 02:10:44 PM
#9891   Drug man, Emerald Isle 04/16/18 02:09:13 PM
#9890   Where is you documented proof they have sales? drugmanrx 04/16/18 01:49:26 PM
#9889   Yman, So where’s the link to “why some penny Emerald Isle 04/16/18 01:26:04 PM
#9888   What everyone should know: yman 04/16/18 12:14:00 PM
#9887   Something to read and do during lunch. drugmanrx 04/16/18 09:42:26 AM
#9886   Druggman, Just up for work so I’ll address a Emerald Isle 04/16/18 02:23:56 AM
#9885   Emerald the reality is that the only way drugmanrx 04/15/18 08:51:22 PM
#9884   No, almost no pink sheet companies and many Emerald Isle 04/15/18 05:39:53 PM
#9883   Sorry, to break this to you Emerald, but drugmanrx 04/15/18 04:03:02 PM
#9882   All, Emerald Isle 04/15/18 01:25:27 PM
#9881   That's too bad - wish there was someone jshdn 03/13/18 03:32:13 PM
#9880   JSHDN, Not recently. I did speak with him last Emerald Isle 03/13/18 03:05:03 PM
#9879   Hi - do you ever talk to Bret, jshdn 03/13/18 12:27:12 PM
#9878   Gosox12, I have kept a certain number of shares Emerald Isle 03/02/18 11:40:22 AM
#9877   I'm sure they are all good intentioned people yman 03/01/18 10:54:29 AM
#9876   This will remain in limbo until current CEO drugmanrx 03/01/18 10:25:29 AM
#9875   There is always hope. I'm invested and yman 03/01/18 09:50:57 AM
#9874   Oh never mind - I missed the part jshdn 03/01/18 01:54:08 AM
#9873   Sounds grim - what do you think the jshdn 03/01/18 01:21:13 AM
#9872   China, slim to none. If you want to yman 02/28/18 10:16:07 PM
PostSubject